Wall St up after tech selloff as yields retreat; Moderna surges
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Wall St up after tech selloff as yields retreat; Moderna surges" is generating significant coverage in the Business category, with 2 articles from 2 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Investor's Business Daily and CNBC. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 2h ago.
Quick answers
Why is "Wall St up after tech selloff as yields retreat; Moderna surges" trending?
Because 2 independent news sources published 2 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (2)
- Stock Market Today: Dow Gathers Steam On Treasury News; Moderna Soars As Bitcoin Rises (Live Coverage) Investor's Business Daily · 4h ago
- Target earnings, Canada tariffs, American Airlines' seatback screens and more in Morning Squawk CNBC · 4h ago
Topics
Related trends
Moderna Shares Double on Success of mRNA Cancer Vaccine
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma
Merck and Moderna’s melanoma vaccine hits key survival milestones, sending Moderna's stock soaring.
Moderna surges as Merck-partnered melanoma vaccine cuts recurrence in large trial
Moderna stock surges after a partnered melanoma vaccine developed with Merck successfully reduced cancer recurrence in a large-scale clinical trial.
Moderna shares soar 60% on melanoma vaccine trial success
Moderna shares surged up to 60% following the reported success of a large-scale melanoma vaccine trial conducted in partnership with Merck.
Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
Moderna and Merck report that a personalized mRNA cancer vaccine succeeded in a late-stage melanoma trial.
'Spending is leading to earnings': Wall Street strategists see payoff from Big Tech's AI investment
Wall Street strategists suggest Big Tech's massive AI infrastructure investments are finally transitioning from pure spending into a tangible monetization phase.